| Autor: |
Lin, Feng, Rhee, Frits van, Goldman, John M., Cross, Nicholas C.P. |
| Zdroj: |
Blood; May 1996, Vol. 87 Issue: 10 p4473-4478, 6p |
| Abstrakt: |
We prospectively studied 98 chronic myeloid leukemia (CML) patients after bone marrow transplantation by competitive polymerase chain reaction to detect and quantify leukemia-specific BCR-ABL mRNA. Of 69 patients who had persistently undetectable, decreasing, or low BCR-ABL levels (< 50 transcripts/μg RNA) on sequential analysis, one (1%) subsequently relapsed. Of 29 patients who had increasing or persistently high BCR-ABL (>50 transcripts/μg RNA) on sequential analysis, 21 (72%) have relapsed (P< .00001). In 19 patients studied sequentially, a constant logarithmic increase in the number of BCR-ABL transcripts was found before relapse, indicating a constant BCR-ABL transcript doubling time. The doubling time for patients relapsing cyto-genetically or into chronic phase (median, 24.7 days) was significantly longer than that of patients relapsing into advanced phases (median, 14.7 days; P= .005). Eight patients were treated for relapse by donor leukocyte transfusions. The doubling time of responders was significantly longer than that of nonresponders (P= .017). We conclude that quantification of BCR-ABL transcripts after bone marrow transplantation (BMT) is valuable in predicting relapse: a more rapid BCR-ABL transcript doubling time before relapse might indicate a more aggressive disease. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
